Neuronal effects of acute citalopram detected by pharmacoMRI

Anderson IM, Clark L, Elliott R, Kulkarni B, Williams SR, Deakin JF (2002) 5-HT(2C) receptor activation by m-chlorophenylpiperazine detected in humans with fMRI. NeuroReport 13:1547–1551

Attenburrow MJ, Mitter PR, Whale R, Terao T, Cowen PJ (2001) Low-dose citalopram as a 5-HT neuroendocrine probe. Psychopharmacology 155:323–326

Bakker A, van Balkom AJ, van Dyck R (2000) Selective serotonin reuptake inhibitors in the treatment of panic disorder and agoraphobia. Int Clin Psychopharmacol 15:S25–S30

Calhoun VD, Pekar JJ, Pearlson GD (2004) Alcohol intoxication effects on simulated driving: exploring alcohol-dose effects on brain activation using functional MRI. Neuropsychopharmacology 29:2017–2097

Clemett DA, Punhani T, Duxon MS, Blackburn TP, Fone KCF (2000) Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS. Neuropharmacology 39:123–132

Deakin JFW (2003) Depression and antisocial personality disorder: two contrasting disorders of 5-HT function. J Neural Transm 64:79–93

Devlina MG, Smitha MG, Ryana OM et al (2004) Regulation of serotonin 5-HT2C receptors by chronic ligand exposure. Eur J Pharmacol 498:59–69

Drevets WC (2000) Neuroimaging studies of mood disorders. Biol Psychiatry 48:813–829

Hervás I, Bel N, Fernández AG, Palacios JM, Artigas F (1998) In vivo control of 5-hydroxytryptamine release by terminal autoreceptors in rat brain areas differentially innervated by the dorsal and median raphe nuclei. Naunyn-Schmiedeberg’s Arch Pharmacol 358:315–322

Himberg J, Hyvarinen A, Esposito F (2004) Validating the independent components of neuroimaging time series via clustering and visualization. NeuroImage 22:1214–1222

Houston GC, Papadakis NG, Carpenter TA, Hall LD, Mukherjee B, James MF, Huang CL (2001) Mapping of brain activation in response to pharmacological agents using MRI in the rat. Magn Reson Imaging 19:905–919

Keller MB (2000) Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials. J Clin Psychiatry 61:896–908

Lee K, Dixon AK, Pinnock RD (1999) Serotonin depolarizes hippocampal interneurones in the rat stratum oriens by interaction with 5-HT2 receptors. Neurosci Lett 270:56–58

Marazziti D, Rossi A, Giannaccini G, Zavaglia KM, Dell’Osso L, Lucacchini A, Cassano GB (1999) Distribution and characterization of [3H]mesulergine binding in human brain postmortem. Eur Neuropsychopharmacol 10:21–26

Mayberg HS, Brannan SK, Tekell JL et al (2000) Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response serial metabolic changes with fluoxetine. Biol Psychiatry 48:830–843

McBean DE, Ritchie IM, Olverman HJ, Kelly PAT (1999) Effects of the specific serotonin reuptake inhibitor, citalopram, upon local cerebral blood flow and glucose utilisation in the rat. Brain Res 847:80–84

Penttila J, Syvalahti E, Hinkka S, Kuusela T, Scheinin H (2001) The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system: a randomised placebo-controlled study on healthy volunteers. Psychopharmacology 154:343–349

Schmithorst VJ, Holland SK (2004) Comparison of three methods for generating group statistical inferences from independent component analysis of functional magnetic resonance imaging data. J Magn Reson Imaging 19:365–368

Seifritz E, Baumann P, Muller MJ, Annen O, Amey M, Hemmeter U, Hatzinger M, Chardon F, Holsboer-Trachsler E (1996) Neuroendocrine effects of a 20-mg citalopram infusion in healthy males: a placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology 14:253–263

Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22–33

Shoaib M, Lowe AS, Williams SC (2004) Imaging localised dynamic changes in the nucleus accumbens following nicotine withdrawal in rats. NeuroImage 22:847–854

Spitzer RL, Williams JB, Gibbon M, First MB (1992) The Structured Clinical Interview for DSM-III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry 49:624–629

Wise RG, Rogers R, Painter D, Bantick S, Ploghaus A, Williams P, Rapeport G, Tracey I (2002) Combining fMRI with a pharmacokinetic model to determine which brain areas activated by painful stimulation are specifically modulated by remifentanil. NeuroImage 22:847–854

Zohar J, Insel TR, Zohar-Kadouch RC, Hill JL, Murphy DL (1988) Serotonergic responsivity in obsessive–compulsive disorder. Effects of chronic clomipramine treatment. Arch Gen Psychiatry 45:167–172